Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 38Carcinoma, Non-Small-Cell Lung 23Stomach Neoplasms 19Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Esophageal Squamous Cell Carcinoma 17Esophageal Neoplasms 16Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Liver Neoplasms 6Cholangiocarcinoma 6Lung Neoplasms 5Hodgkin Disease 5Biliary Tract Neoplasms 5Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Urinary Bladder Neoplasms 2

Interventions

Cyclophosphamide 46fludarabine phosphate 34Peripheral Blood Stem Cell Transplantation 29Whole-Body Irradiation 22Etoposide 22Tacrolimus 20Methotrexate 20Mycophenolic Acid 19Cytarabine 19Dexamethasone 17Vincristine 16Filgrastim 16Busulfan 16venetoclax 15Antilymphocyte Serum 15Rituximab 13Prednisone 13Cyclosporine 12Doxorubicin 11Melphalan 9Calcium Dobesilate 9nelarabine 8Bortezomib 8merphos 7Radiotherapy 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7prednylidene 6pegaspargase 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × camrelizumab × Clear all
NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 1/2 Recruiting
43 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡